We found that the FOXO1 was highly expressed in ALL patients with ETV6-RUNX1 fusion (a well-known excellent prognosis group) and significantly low expression in ALL subtypes with known poor prognosis (e.g., infantile leukemia, KMT2A-rearranged, and T-ALL), and this pattern was confirmed in different cohorts (33). This evidence concerns the gene FOXO1 and acute lymphoblastic leukemia.